News Column

New Small Interference RNAs (siRNAs) Findings from China University of Science and Technology Discussed (Cationic Lipid-Assisted Polymeric...

September 10, 2014



New Small Interference RNAs (siRNAs) Findings from China University of Science and Technology Discussed (Cationic Lipid-Assisted Polymeric Nanoparticle Mediated GATA2 siRNA Delivery for Synthetic Lethal Therapy of KRAS Mutant Non-Small-Cell ...)

By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Small Interference RNAs (siRNAs) are presented in a new report. According to news reporting originating from Anhui, People's Republic of China, by NewsRx correspondents, research stated, "Synthetic lethal interaction provides a conceptual framework for the development of wiser cancer therapeutics. In this study, we exploited a therapeutic strategy based on the interaction between GATA binding protein 2 (GATA2) downregulation and the KRAS mutation status by delivering small interfering RNA targeting GATA2 (siGATA2) with cationic lipid-assisted polymeric nanoparticles for treatment of non-small-cell lung carcinoma (NSCLC) harboring oncogenic KRAS mutations."

Our news editors obtained a quote from the research from the China University of Science and Technology, "Nanoparticles carrying siGATA2 (NPsiGATA2) were effectively taken up by NSCLC cells and resulted in targeted gene suppression. NPsiGATA2 selectively inhibited cell proliferation and induced cell apoptosis in KRAS mutant NSCLC cells. However, this intervention was harmless to normal KRAS wild-type NSCLC cells and HL7702 hepatocytes, confirming the advantage of synthetic lethality-based therapy."

According to the news editors, the research concluded: "Moreover, systemic delivery of NPsiGATA2 significantly inhibited tumor growth in the KRAS mutant A549 NSCLC xenograft murine model, suggesting the therapeutic promise of NPsiGATA2 delivery in KRAS mutant NSCLC therapy."

For more information on this research see: Cationic Lipid-Assisted Polymeric Nanoparticle Mediated GATA2 siRNA Delivery for Synthetic Lethal Therapy of KRAS Mutant Non-Small-Cell Lung Carcinoma. Molecular Pharmaceutics, 2014;11(8):2612-2622. Molecular Pharmaceutics can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)

The news editors report that additional information may be obtained by contacting S. Shen, China University of Science & Technology, High Magnet Field Lab CAS, Hefei 230026, Anhui, People's Republic of China. Additional authors for this research include C.Q. Mao, X.Z. Yang, X.J. Du, Y. Liu, Y.H. Zhu and J. Wang (see also Small Interference RNAs (siRNAs)).

Keywords for this news article include: Anhui, People's Republic of China, Asia, Bronchial Neoplasms, Bronchogenic Carcinoma, Emerging Technologies, Genetics, Lung Diseases, Lung Neoplasms, Nanoparticle, Nanotechnology, Non-Small Cell Lung Cancer, Non-Small-Cell Lung Cancer, Oncology, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Small Cell Carcinoma, Small Interference RNAs, Small Interference RNAs (siRNAs), Therapy, siRNA

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters